Colorectal Cancer | Norton Healthcare

Indication: Colorectal Cancer

Phase II study for the treatment of HER2- positive locally advanced unresectable or metastatic colorectal cancer subjects (CRC)

Sub-indication: Gastrointestinal Cancer

Drug Study

Principal Investigator: Michael Driscoll, M.D.
Norton Cancer Institute

Sponsor: Daiichi Sankyo Company, Limited

Learn more at

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.